Full Text View
Tabular View
No Study Results Posted
Related Studies
Loxapine and Weaning From Ventilator
This study has been completed.
Study NCT00122733   Information provided by Assistance Publique - Hôpitaux de Paris
First Received: July 19, 2005   Last Updated: July 20, 2007   History of Changes

July 19, 2005
July 20, 2007
December 2005
 
  • cessation of agitation [ Time Frame: 3 hours ]
  • improvement in the clinical and biological parameters of weaning trial [ Time Frame: 3 hours ]
  • cessation of agitation
  • improvement in the clinical and biological parameters of weaning trial
Complete list of historical versions of study NCT00122733 on ClinicalTrials.gov Archive Site
 
 
 
Loxapine and Weaning From Ventilator
Facilitation of Weaning From Ventilator by Loxapine

Patients may be very agitated during the weaning period from mechanical ventilation. Administration of loxapine, a neuroleptic that does not notably affect ventilatory drive, may help in obtaining an adequate level of cooperation and, therefore, in reducing the duration of mechanical ventilation.

Mechanical ventilation is a life-saving procedure in critically ill patients. This procedure is however not devoid of risks and every effort should be made to shorten its duration. This is best accomplished by the implementation of weaning protocols. Sedation (by opiates and benzodiazepines) is often required in such patients for their comfort and adaptation to the respirator. Withdrawal of sedation in order to allow patients to resume spontaneous breathing may be associated with agitation and confusion that may hinder weaning. In such cases, reinstitution of heavy sedation will prolong ventilator-dependency. It may therefore be interesting to administer a neuroleptic (loxapine) with good anxiolytic properties but that does not notably interfere with spontaneous breathing ability.

Patients will be included when they fail a spontaneous ventilation trial (see inclusion criteria) because of marked agitation. Usual simple clinical (respiratory frequency, P01 measured on the respirator, arterial pressure, cardiac rate) and biological criteria (arterial blood gas determination) and a measurement of sedation/agitation with validated scales (Richmond agitation sedation scale, Ramsay score) will be gathered when a patient is deemed ready for a trial of spontaneous ventilation for weaning. In cases of marked agitation according to validated scales, patients will be given a conventional dose (150 mg) of loxapine by the nasogastric tube and the efficacy of this treatment will be evaluated on the same parameters as above. Demonstration of the facilitation of weaning by this simple strategy would be useful in order to reduce risks associated with mechanical ventilation.

 
Interventional
Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
  • Respiratory Insufficiency
  • Psychomotor Agitation
Drug: loxapine
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
9
December 2006
 

Inclusion Criteria:

  • Patients who are eligible for weaning from the respirator (FIO2 less than 50%; positive end expiratory pressure [PEEP] level less than 6 cmH2O)
  • Patients whose agitation (according to accepted scores) during a weaning trial precludes extubation

Exclusion Criteria:

  • History of convulsions or epilepsy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00122733
 
LMR2
Assistance Publique - Hôpitaux de Paris
 
Principal Investigator: Guillaume CHEVREL, MD Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
July 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP